Karuna Therapeutics Inc expected to post a loss of $2.11 a share - Earnings Preview

Karuna Therapeutics

02/05/2022 19:33

* Karuna Therapeutics Inc  KRTX.OQ   KRTX.O  is expected
to show
no change in quarterly revenue when it reports  results on May 4
(estimated). 
    * ​Refinitiv's mean analyst estimate for Karuna Therapeutics
Inc
is for a loss of $2.11 per share. For the same quarter last
year, the company reported a loss of $1.07 per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 17 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Karuna
Therapeutics Inc is $179.5​, above​ its last closing price
of $111.46. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -1.66       -1.73      -0.94     Beat    45.8
 Sep. 30 2021  -1.45       -1.44      -1.72     Missed  -19.4
 Jun. 30 2021  -1.30       -1.34      -1.17     Beat    12.5​
 Mar. 31 2021  -1.16       -1.13      -1.07     Beat    5.4
 ​​Dec.        -0.90       -0.90      -0.89     Beat    0.6
 31 2020                                                
 Sep. 30 2020  -0.79       -0.82      -0.71     Beat    13.6​
 Jun. 30 2020  -0.43       -0.45      -0.65     Missed  -43.1
 Mar. 31 2020  -0.39       -0.41      -0.33     Beat    18.1
 This summary was machine generated May 2 at 18:33 GMT.  All
figures in US dollars  unless otherwise stated